Andromeda Biotech: A drug for type 1 diabetes

The treated patients in the double-blinded study of DiaPep 277 showed significantly better pancreas function that the control group.

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way. In addition, all of the patients received insulin as needed to stabilize their .

DiaPep277 was invented by Prof. Irun Cohen and his team at the Weizmann Institute of Science. This unique peptide, containing 24 , is derived from the sequence of the human 60 (Hsp60). The peptide acts by modulating the immune system, preventing the destruction of the that secrete insulin and preserving their natural function. Treatment of Type 1 with DiaPep277 may have several medical benefits: slowing the deterioration of the , improved metabolic control, a reduction in daily insulin requirements and fewer complications of diabetes.

During the trial, the ability of the patients' pancreas to secrete insulin was tested. From an initial analysis of the results, it appears that the patients treated with the drug for a year or more had significantly higher pancreas function than those in the control group.

From the point of view of safety, no significant differences were found in the incidence of side effects between the treated and control groups.

Additional data on the drug's efficacy and safety were collected and evaluated, and these will be presented in a final report on the trial, which will be completed in several months.

Andromeda Biotech is now planning to conduct another trial, to try to reproduce these results. Recruitment of patients into this trial is expected to be finalized in the second quarter of 2012. The research and development team of Andromeda Biotech emphasize that the drug is still under development, and there is no absolute guarantee that the drug will eventually be marketed.

add to favorites email to friend print save as pdf

Related Stories

Promising results of Phase I diabetes trial announced

Jun 26, 2011

Promising results of the Phase I clinical trial of the generic drug BCG (bacillus Calmette-Guerin) to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego. ...

Promising kidney drug fails in large clinical trial

Oct 27, 2011

What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN) ...

Recommended for you

Saudi Arabia reports pilgrim infected with MERS

1 hour ago

In the past 24 hours, Saudi Arabia has reported four new deaths from a Middle East virus related to SARS and 36 more cases of infection, including a Turkish pilgrim in Mecca.

User comments